Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 1;105(9):2072-2079.
doi: 10.1097/TP.0000000000003839.

Impact of COVID-19 on Lung Allograft and Clinical Outcomes in Lung Transplant Recipients: A Case-control Study

Nitipong Permpalung  1   2 , Katrina Bazemore  3 , Teresa Po-Yu Chiang  4 , Joby Mathew  3 , Lindsay Barker  3 , Saman Nematollahi  1 , Willa Cochran  4 , Afrah S Sait  1 , Robin K Avery  1 , Pali D Shah  3
Affiliations

Impact of COVID-19 on Lung Allograft and Clinical Outcomes in Lung Transplant Recipients: A Case-control Study

Nitipong Permpalung et al. Transplantation. .

Abstract

Background: The impacts of COVID-19 on lung allograft function, rejection, secondary infection, and clinical outcomes in lung transplant recipients (LTRs) remain unknown.

Methods: A 1:2 matched case-control study was performed to evaluate rehospitalization, lung allograft function, and secondary infections up to 90 d after COVID-19 diagnosis (or index dates for controls).

Results: Twenty-four LTRs with COVID-19 (cases) and 48 controls were identified. Cases and controls had similar baseline characteristics and lung allograft function. LTRs with COVID-19 had higher incidence of secondary bacterial infection (29.2% versus 6.3%, P = 0.008), readmission (29.2% versus 10.4%, P = 0.04), and for-cause bronchoscopy (33.3% versus 12.5%, P = 0.04) compared with controls. At d 90, mortality in cases versus controls was 8.3% versus 2.1% (P = 0.21), incidence of invasive fungal infections in cases versus controls was 20.8% versus 8.3% (P = 0.13) and forced expiratory volume in 1 s (FEV1) decline ≥10% from baseline occurred in 19% of cases versus 12.2% of controls (P = 0.46). No acute cellular rejection, acute antibody-mediated rejection, or new donor-specific anti-HLA antibodies were observed among cases or controls within 90 d post index date.

Conclusions: We found LTRs with COVID-19 were at risk to develop secondary infections and rehospitalization post COVID-19, compared with controls. While we did not observe post viral acute cellular rejection or antibody-mediated rejection, further studies are needed to understand if LTRs with COVID-19 who did not recover baseline lung function within 90 d have developed chronic lung allograft dysfunction stage progression.

PubMed Disclaimer

Conflict of interest statement

N.P. served on the Advisory Board for Shionogi Inc. and received research support from Health Systems Research Institute (Thailand), the Fisher Center Discovery Program (Johns Hopkins), Cystic Fibrosis Foundation, and Cidara. SN has received grant support from the Fisher Center Discovery Program (Johns Hopkins). RKA has received grant support from Aicuris, Astellas, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. PDS has received grant support from Ansun Biopharma, Breath Therapeutics Cystic Fibrosis Foundation and National Institute of Health. The other authors declare no conflicts of interest.

References

    1. Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplantg. 2020;20:1809–1818.
    1. Avery RK. COVID-19 therapeutics for solid organ transplant recipients; 6 months into the pandemic: where are we now? Transplantation. 2021;105:56–60.
    1. Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020;20:1941–1943.
    1. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808.
    1. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20:1849–1858.

Publication types

MeSH terms